Europe
In order to have full control of J&J’s product, the production of the AstraZeneca vaccine, which was being conducted at the same facility, will move elsewhere.
It was a busy week for clinical trial news. Here’s a look.
It’s something of the holy grail—run whole genome sequencing on a sample of a person’s blood and identify their risk for disease, all quickly and affordably. Oxford, England’s Genomics, founded in 2014 out of Oxford University by Sir Peter Donnelly, may be getting close.
A current Phase III trial of the Pfizer-BioNTech COVID-19 vaccine has confirmed the protection remains high for at least six months after the second dose. In a statement, Pfizer and BioNTech reported the vaccine was 91.3% effective against the disease.
In a statement, the company said, “Bristol Myers Squibb is in compliance with all applicable tax rules and regulations. We work with leading experts in this area and will continue to work cooperatively with the IRS to resolve this matter. Beyond that, we don’t comment on ongoing regulatory matters.”
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Will We Need COVID-19 Vaccines Every Year? Although the jury is still out, a study out of Charité – Universitätsmedizin Berlin suggests that the answer is yes for a few years, but may be unnecessary after a few years post-pandemic.
The U.S. Food and Drug Administration approved two new treatments for multiple myeloma and pulmonary hypertension.
QED Therapeutics, an affiliate of BridgeBio Pharma, announced today their global collaboration and licensing agreement with Helsinn Group.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
PRESS RELEASES